The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—announces 2024 award recipients that include individuals and groups who have made significant and noteworthy impacts on improving cancer care and supporting NCCN’s mission to help all people with cancer to live better lives.
New research in the April 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer.
The National Comprehensive Cancer Network (NCCN) and the NCCN Foundation announce five winners for the 2024 NCCN Foundation Young Investigator Awards (YIA).
More than 1,700 oncology professionals attended National Comprehensive Cancer Network meeting in Orlando and online, featuring clinical and administrative updates for improving cancer care worldwide, plenary sessions on Lynch syndrome and drug shortages, plus nearly 200 poster abstracts with new research.
The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
Taneal D. Carter, MS, MPA, Manager of Cancer Care Equity Program for NCCN, has been named one of 2024’s ‘40 Under 40’ by the National Minority Quality Forum (NMQF). Visit NCCN.org/equity for more information.
Recent NCCN Guidelines updates—along with the supporting evidence—will be presented during the NCCN 2024 Annual Conference held in Orlando, Florida April 5-7, and simultaneously online. Visit NCCN.org/conference to learn more and register.
Two new measurements have been added to the Health Equity Report Card (HERC)—a tool for improving the quality and equity of cancer care. This expansion is part of ongoing efforts to address the impact of structural and interpersonal racism as a cause of disparities in cancer outcomes in the United States.
New NCCN Guidelines for Neuroblastoma address the importance and impact of risk stratification for treating one of the more common types of pediatric solid tumors; includes vanguard treatment recommendations involving multimodality treatment for high-risk disease.
For World Cancer Day, February 4th, NCCN, ACS CAN, and NMQF are announcing three key areas of policy focus as part of the Alliance for Cancer Care Equity (ACCE) joint collaboration, including advancing diversity in clinical trials, improving cancer screening and early detection, and increasing access to patient navigation.
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading academic cancer centers in the United States—is celebrating six years of working alongside the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI), as part of Allied Against Cancer.
The National Comprehensive Cancer Network’s Oncology Research Program selects projects to evaluate the effectiveness of elranatamab in the treatment of multiple myeloma.
New research results in JNCCN are encouraging regarding the benefit of immunotherapy for treating lung cancer across racial and ethnic groups, but also reinforce need to include more Black and Hispanic people in cancer clinical trials and highlight the importance of equitable treatment delivery for closing disparities in outcomes.
NCCN—an alliance of leading cancer centers—hosted a Patient Advocacy Summit to explore the role of navigation throughout the cancer process. A diverse group of subject matter experts addressed the impact patient navigation has on care and how to utilize navigators to reduce economic burdens and disparities in care.
The Latin American and Caribbean Society of Medical Oncology (SLACOM) and National Comprehensive Cancer Network (NCCN) host the Latin American Regional Breast Cancer Summit: Advocating and Implementing Guideline-Concordant Cancer Care for Patients. Esteemed experts from Argentina, Brazil, Mexico, Columbia, Peru, and the United States present challenges, barriers, and potential solutions for improving access to guideline-concordant breast cancer care in the Latin American region.
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced grants awarded for developing innovative investigator-initiated research involving the medication relugolix.
New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that breast cancer patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy.
National Comprehensive Cancer Network publishes free NCCN Guidelines for Patients with information on improving well-being and reducing suffering and distress for people with cancer; available at NCCN.org/patientguidelines.
New research in JNCCN finds that removing as much tumor as possible in multiorgan metastatic colorectal cancer—via various methods—did not cause a decrease in quality of life despite an increase in adverse events; survival benefits remain unclear.
72% of the centers surveyed by NCCN continue to experience a shortage of carboplatin and 59% are still seeing a shortage of cisplatin. Overall, 86% of centers surveyed reported experiencing a shortage of at least one type of anti-cancer drug.
Evelyn Handel Zapata, PharmD, BCPS, BCOP, Senior Director of Drugs & Biologics Programs at the National Comprehensive Cancer Network® (NCCN®) was named a 40 Under 40 in Cancer: Emerging Leader; launches new resources for a type of pediatric lymphoma.
NCCN 2023 Annual Congress: Hematologic Malignancies features expert perspectives on developments in blood cancer treatment, including NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Updates, CAR T-Cell therapy, BTK Inhibitors, Bispecific T-Cell Engagers, and More. The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square.
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—presented new recommendations for screening and addressing health-related social needs (HRSN) in people with cancer during a policy summit in Washington, D.C.
New NCCN Guidelines for Patients: Blood Clots and Cancer provides much-needed education about recognizing and preventing the rarely-discussed cancer-associated consequence that is a major cause of death and morbidity
New study in JNCCN from the University of Michigan found English speakers who call a hospital general information line were able to get information on next steps to access cancer care 94% of the time, compared to 38% for Spanish speakers and just 28% for Mandarin speakers.
The National Comprehensive Cancer Network’s Oncology Research Program selects projects focused on reducing gaps in patient care for people with limited-stage (LS) and extensive stage (ES) small cell lung cancer.
The National Comprehensive Cancer Network (NCCN)—a not-for-profit alliance of leading academic cancer centers—announces Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO), replacing the retiring longtime CEO, Robert W. Carlson, MD.
The National Comprehensive Cancer Network (NCCN) today announces the publication of NCCN Guidelines for Patients: Hodgkin Lymphoma in Children.
The National Comprehensive Cancer Network expands materials tailored for the MENA region to help improve patient outcomes by standardizing local cancer care; includes new adaptation focused on genetic/familial cancer risk, as well as care for ovarian/fallopian tube/primary peritoneal cancers.
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) today announced new grants awarded to improve quality initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer.
JNCCN study sheds light on a rapid shift in practice evolution by oncologists treating people with colon cancer adjuvantly after primary surgery, following publications from the IDEA collaboration.
Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—convened a policy summit to examine how geography impacts cancer outcomes.
The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London.
New research in the June 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network found that when alectinib—a safe and effective small molecule kinase inhibitor used to treat some types of advanced lung cancer—was taken with a fuller breakfast, or with lunch, it resulted in significantly higher drug concentrations than when taken with a low-fat breakfast.
National Comprehensive Cancer Network’s Department of Policy and Advocacy calls on Federal Government, pharmaceutical industry, providers, and payers to work together on solutions, as 93% of cancer centers surveyed report a shortage of carboplatin and 70% report shortages for cisplatin; two medications that are used in combination to cure many types of cancer.
United States-based NCCN representatives visit Hanoi, Vietnam to work with local experts to improve quality-of-life for patients with cancer throughout the country.
Katy Winckworth-Prejsnar, MPH, Senior Manager of Global Policy and Strategic Alliances for National Comprehensive Cancer Network (NCCN), to Co-Chair Non-Communicable Diseases Roundtable for the Global Health Council (GHC)
Research from Moffitt Cancer Center, in the May 2023 issue of JNCCN, assessed patient experiences with telemedicine visits long after the initial pandemic period, finding patients rank it superior for access to care and provider engagement.
Theresa J. Franco, Fred & Pamela Buffett Cancer Center; F. Marc Stewart, City of Hope National Medical Center; Douglas E. Wood, UW Medicine Fred Hutchinson Cancer Center; and Donna Powell, NCCN, presented with awards during NCCN 2023 Annual Conference.
NCCN has published a new addition to its library of patient resources, expanding the information available for breast cancer. The new NCCN Guidelines for Patients: Inflammatory Breast Cancer joins patient and caregiver resources for Breast Cancer Screening and Diagnosis, Ductal Carcinoma In Situ, Invasive Breast Cancer, and Metastatic Breast Cancer.
The National Comprehensive Cancer Network (NCCN) and the NCCN Foundation announce four winners for the 2023 NCCN Foundation Young Investigator Awards. These annual awards honor up-and-coming leaders in oncology research working to investigate and advance cancer care.
The NCCN 2023 Annual Conference took place in-person in Orlando and virtually, with a particular focus on human connection. That connection was underscored with more than 2,000 registrants from across the continuum of cancer care, including approximately 1,000 who returned in-person for the first time since 2019. Educational sessions highlighted the importance of ensuring care meets the latest standards while also rejecting a one-size-fits-all approach.
New research in the April 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that specially trained oncology infusion room nurses can improve advance care planning (ACP) for patients with advanced cancer. As compared to patients who received standard care, those who participated in targeted and specialized intervention had a dramatically increased rate of creating advance directives and taking part in conversation about end-of-life issues.
The National Comprehensive Cancer Network (NCCN) announces the addition of the University of Chicago Medicine Comprehensive Cancer Center as the newest Member Institution to join the not-for-profit alliance of leading cancer centers.
A first-of-its-kind study in the March 2023 issue of JNCCN highlights how the lack of genomic research for people with African ancestry, particularly those from the Sub-Saharan region, is hampering efforts to reduce disparities for people with advanced prostate cancer.
NCCN 2023 Annual Conference featuring more than a thousand worldwide oncology professionals will present new research findings, latest NCCN Guidelines updates, and best practices for achieving quality cancer care delivery, in Orlando and online March 31—April 2, 2023. Visit NCCN.org/conference for more.
The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading United States cancer centers—announces a new collaboration with the Institute of Hematology and Transfusion Medicine in Poland (IHIT), and the Alliance For Innovation—Polish-American Foundation (AFI).
New research in the February 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network illustrates how the use of an algorithm to calculate a patient-reported symptom complexity score can help oncologists identify patients who are at increased risk for unplanned visits to the emergency department (ED), creating the potential for additional proactive care, and the reduction of healthcare costs.
An ongoing pilot project aims to evaluate the feasibility of implementing the Health Equity Report Card (HERC) as a tool for improving the quality and equity of cancer care and continues the Elevating Cancer Equity collaboration from the National Comprehensive Cancer Network (NCCN), American Cancer Society Cancer Action Network (ACS CAN), and National Minority Quality Forum (NMQF)--highlighted on World Cancer Day.
National Comprehensive Cancer Network’s new Diversity, Equity, & Inclusion (DEI) Directors Forum is working together to improve diversity of clinical staff representation across nation’s leading academic cancer centers.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
